Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Apixaban OR eliquis OR BMS562247 OR BMS-562247 OR 503612-47-3 OR "BMS 562247"

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    90 result(s) found for: Apixaban OR eliquis OR BMS562247 OR BMS-562247 OR 503612-47-3 OR "BMS 562247". Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2021-002298-25 Sponsor Protocol Number: 20203331 Start Date*: 2021-09-15
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP)
    Full Title: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002636-13 Sponsor Protocol Number: 001 Start Date*: 2017-04-28
    Sponsor Name:Oslo University Hospital
    Full Title: Study of Antithrombotic Treatment after Intracerebral Haemorrhage (STATICH)
    Medical condition: We want to study patients with indication for antithrombotic drugs who suffers from spontaneous intracerebral hemorrhage (ICH). It has long been unclear whether survivors of ICH should start antith...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005351-14 Sponsor Protocol Number: CV185-035 Start Date*: 2007-05-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surg...
    Medical condition: Subjects undergoing elective total hip replacement (THR) surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051055 Deep vein thrombosis LLT
    9.1 10037377 Pulmonary embolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) BE (Completed) GB (Completed) DK (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005503-84 Sponsor Protocol Number: AFNET8 Start Date*: 2018-02-14
    Sponsor Name:Kompetenznetz Vorhofflimmern e.V.
    Full Title: A Safety Study Assessing Oral Anticoagulation with Apixaban versus Vitamin-K Antagonists in Patients with Atrial Fibrillation and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment.
    Medical condition: End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment and Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    23.1 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002708-38 Sponsor Protocol Number: 131313 Start Date*: 2020-10-26
    Sponsor Name:Department of Medical Science Gothenburg University
    Full Title: Optimized pharmacological treatment for broken heart (takotsubo) syndrome
    Medical condition: The medical condition is acute heart failure (Takotsubo syndrome)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003621-28 Sponsor Protocol Number: 5072018 Start Date*: 2019-07-23
    Sponsor Name:IUCPQ
    Full Title: Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES study.
    Medical condition: Device thrombosis at 2 months and 12 months after left atrial appendage closure (LAAC) Ischemic events (stroke, TIA) at 2-month and 1-, 2-, 3-, 4-and 5-year follow-up Bleeding events at 2-month an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10047065 - Vascular disorders 10005103 Bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003677-33 Sponsor Protocol Number: 7210 Start Date*: 2018-02-02
    Sponsor Name:Leiden University Medical Center
    Full Title: The Need for Titration or Monitoring of Direct Oral Anticoagulant Treatment: The MONDOAC and KIDOAC study
    Medical condition: patients who are diagnosed with atrial fibrillation or venous thrombosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002433-31 Sponsor Protocol Number: 29BRC17.0125 Start Date*: 2017-09-13
    Sponsor Name:CHRU de BREST
    Full Title: REduced dose versus full-dose of direct oral anticoagulant after uNprOvoked Venous thromboEmbolism. The RENOVE open-label, randomized, controlled trial
    Medical condition: Patients with indications for long-term anticoagulation after VTE (i.e.; symptomatic PE or proximal DVT) initially treated during 6 to 12 months with anticoagulant therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10047249 Venous thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000393-11 Sponsor Protocol Number: NL60426 Start Date*: 2017-09-07
    Sponsor Name:University Medical Center utrecht
    Full Title: ’Switching anticoagulant management from a VKA to a NOAC-based treatment strategy in frail elderly patients with atrial fibrillation (FRAIL-AF study)
    Medical condition: Atrial Fibrilation
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000315-24 Sponsor Protocol Number: 1208182 Start Date*: 2013-06-18
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: Pharmaco-epidemiology of the treatment of the symptomatic pulmonary embolism among in-patients and 75 years old or more: prospective, multicentric "PEAGE" cohort
    Medical condition: Symptomatic pulmunory embolism on patients over 75 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001554-61 Sponsor Protocol Number: ACASA-TAVI-2.1 Start Date*: 2021-08-19
    Sponsor Name:Oslo University Hospital
    Full Title: Anti-Coagulation versus AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation (ACASA-TAVI)
    Medical condition: Patients with aortic stenosis undergoing transcatheter aortic valve implantation.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006514-37 Sponsor Protocol Number: DOAC-CO Start Date*: 2023-02-08
    Sponsor Name:Ente Ecclesiastico Ospedale Generale Regionale “F. Miulli”
    Full Title: Haemorrhagic risk of direct oral anticoagulants (DOACs) in patients undergoing oral surgery
    Medical condition: Patients on direct acting oral anticoagulants (DOACs) who are to undergo oral surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007521 Cardiac arrhythmias HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004652-15 Sponsor Protocol Number: 29BRC20.0263 Start Date*: 2021-06-08
    Sponsor Name:CHRU de Brest
    Full Title: AVAJAK: Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myelo-proliferative neoplasms
    Medical condition: Myelo-proliferative neoplasms including essential thrombocythemia, Polycythemia Vera, Prefibrotic myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015494 Essential thrombocythemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036061 Polycythemia vera LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003361-19 Sponsor Protocol Number: H-19078792 Start Date*: 2020-09-07
    Sponsor Name:Rigshospitalet
    Full Title: Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter bioprosthetic aortic valves The Nordic Aortic Val...
    Medical condition: Patients who have undergone successful transcatheter bioprosthetic aortic valve implantation (TAVI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10077017 TAVI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002529-39 Sponsor Protocol Number: PHRC2015-07 Start Date*: 2017-08-30
    Sponsor Name:CHU Angers
    Full Title: Intérêt de l’administration de charbon Activé pour les patients ayant un geste invasif reporté dû à un traitement Anticoagulant Oral Direct
    Medical condition: fibrillation auriculaire ou une maladie veineuse thromboembolique
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002620-17 Sponsor Protocol Number: 18-513 Start Date*: 2019-01-08
    Sponsor Name:Portola Pharmaceuticals, Inc
    Full Title: A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR
    Medical condition: Oral FXa inhibitor-treated patients with acute intracranial bleeding.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10075279 Anticoagulant reversal therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) NL (Completed) ES (Prematurely Ended) GR (Completed) CZ (Completed) LV (Completed) FI (Prematurely Ended) NO (Prematurely Ended) LT (Prematurely Ended) PL (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004138-12 Sponsor Protocol Number: TAK-330-3001 Start Date*: 2022-04-11
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial with Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of PROTHROMPLEX TOTAL for the Rever...
    Medical condition: Patients on treatment with Factor Xa Inhibitor needing for an urgent intervention associated with a high risk of bleeding.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10075279 Anticoagulant reversal therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001785-26 Sponsor Protocol Number: 14-505 Start Date*: 2016-02-15
    Sponsor Name:Portola Pharmaceuticals, Inc.
    Full Title: Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4).
    Medical condition: Uncontrolled bleeding in patients who have taken either a direct factor Xa inhibitor (novel oral anticoagulants) or an indirect factor Xa inhibitor (low molecular weight heparins).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022097 10075279 Anticoagulant reversal therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BE (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001418-12 Sponsor Protocol Number: NCT04483583 Start Date*: 2021-06-24
    Sponsor Name:University of Florida
    Full Title: Tailoring P2Y12 Inhibiting Therapy in Patients requiring Oral Anticoagulation after undergoing Percutaneous Coronary Intervention: The Switching Anti-Platelet and Anti-Coagulant Therapy – 2 Study
    Medical condition: Efficacy of antiplatelet therapy after percutaneous coronary intervention in patients using oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005410-19 Sponsor Protocol Number: HH-AT-001 Start Date*: 2013-03-11
    Sponsor Name:Jessaziekenhuis Hasselt
    Full Title: Developing a Patient Model of Controlled, Radial Artery Access Site Bleeding for Deciding on Anticoagulation Reversal in Patients Treated by Systemic Anticoagulants.
    Medical condition: With the novel oral anticoagulants, including EDOXABAN-DABIGATRANRIVAROXABAN- APIXABAN, we are entering a new era of anticoagulation for atrial fibrillation (AF) (and deep vein thrombosis). Neve...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10022891 - Investigations 10060319 Anticoagulation drug level therapeutic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:51:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA